Contemporary Trends in the Use and Outcomes of Surgical Treatment of Tricuspid Regurgitation by Alqahtani, Fahad et al.
Faculty Scholarship 
2017 
Contemporary Trends in the Use and Outcomes of Surgical 
Treatment of Tricuspid Regurgitation 
Fahad Alqahtani 
Chalak O. Berzingi 
Sami Aljohani 
Mohamad Hijazi 
Ahmad Al-Hallak 
See next page for additional authors 
Follow this and additional works at: https://researchrepository.wvu.edu/faculty_publications 
 Part of the Medicine and Health Sciences Commons 
Authors 
Fahad Alqahtani, Chalak O. Berzingi, Sami Aljohani, Mohamad Hijazi, Ahmad Al-Hallak, and Mohamad 
Alkhouli 
Contemporary Trends in the Use and Outcomes of Surgical Treatment
of Tricuspid Regurgitation
Fahad Alqahtani, MD;* Chalak O. Berzingi, MD;* Sami Aljohani, MD; Mohamad Hijazi, MD; Ahmad Al-Hallak, MD; Mohamad Alkhouli, MD;
Background-—Tricuspid regurgitation (TR), if untreated, is associated with an adverse impact on long-term outcomes. In recent
years, there has been an increasing enthusiasm about surgical and transcatheter treatment of patients with severe TR. We aim to
evaluate the contemporary trends in the use and outcomes of tricuspid valve (TV) surgery for TR using the National Inpatient Sample.
Methods and Results-—Between January 1, 2003 and December 31, 2014, an estimated 45 477 patients underwent TV surgery
for TR in the United States, of whom 15% had isolated TV surgery and 85% had TV surgery concomitant with other cardiac surgery.
There was a temporal upward trend to treat sicker patients during the study period. Patients who underwent isolated TV repair or
replacement had a distinctly different clinical risk profile than those patients who underwent TV surgery simultaneous with other
surgery. Isolated TV replacement was associated with high in-hospital mortality (10.9%) and high rates of permanent pacemaker
implantation (34.1%) and acute kidney injury requiring dialysis (5.5%). Similarly, isolated TV repair was also associated with high in-
hospital mortality (8.1%) and significant rates of permanent pacemaker implantation (10.9%) and new dialysis (4.4%). Isolated TV
repair and TV replacement were both associated with protracted hospitalizations and substantial cost.
Conclusions-—In contemporary practice, surgical treatment of TR remains underused and is associated with high operative
morbidity and mortality, prolonged hospitalizations, and considerable cost. ( J Am Heart Assoc. 2017;6:e007597. DOI: 10.1161/
JAHA.117.007597.)
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S evere tricuspid regurgitation (TR) is prevalent andnegatively affects long-term outcomes.1–5 However, TR
remains undertreated because of the high morbidity and
mortality associated with tricuspid valve (TV) surgery.6–10
Nevertheless, recent developments in the field of tran-
scatheter valve interventions have stimulated a renewed
interest in the “forgotten” TV.11–13 Early in-human experi-
ences demonstrated the feasibility of several transcatheter
tricuspid repair and replacement systems in treating TR, but
they also highlighted the particularly challenging anatomical
features of the TV, subvalvular apparatus, and right ventri-
cle.14–21 A handful of transcatheter TV therapies are being
tested in early feasibility trials (clinicaltrials.gov trial: NCT-
02787408, NCT-02339974, NCT-02574650, NCT-02981953,
NCT-02471807).13 Given the growing interest in tran-
scatheter TV therapies, contemporary outcomes of TV
surgery are relevant and can be used as a benchmark for
early investigations of these therapies. Previous investiga-
tions of TV surgery outcomes included small numbers,
noncontemporary design, or heterogeneous groups of
patients.6–9
We aim to use a large contemporary nationwide registry to
assess characteristics and outcomes of patients undergoing
TV surgery in the United States between January 1, 2003 and
December 31, 2014, with a special emphasis on isolated TV
repair (TVr) and replacement (TVR).
Methods
The data, analytic methods, and study materials are available
to other researchers on request for purposes of reproducing
the results or replicating the procedure. Institutional review
board approval was obtained. Informed consent requirements
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were waived because the data are derived from a nationwide
deidentified database.
Study Data
The Nationwide Inpatient Sample (NIS) was used to derive
patient relevant information between January 2003 and
December 2014. The NIS is the largest publicly available all-
payer administrative claims-based database and contains
information about patient discharges from 1000 nonfederal
hospitals in 45 states. It contains clinical and resource use
information on 5 to 8 million discharges annually, with
safeguards to protect the privacy of individual patients,
physicians, and hospitals. The NIS shares certain similarities
with the Medicare database, including the same International
Classification of Diseases, Ninth Revision, Clinical Modification
(ICD-9-CM) coding system for procedures and diagnoses.
Contrary to the Medicare database, the NIS includes all
payers and patients across all ages. These data are stratified
to represent 20% of US inpatient hospitalizations across
different hospital and geographic regions (random sample).
The national estimates (NEs) represent a calculated estimate
of the total (100%) US hospitalized population. This is
calculated using the Agency for Healthcare Research and
Quality sampling and weighting method. Outcomes analysis
was performed using the actual 20% sample available in the
NIS, whereas the trend analysis was performed using the NE.
This is a standard method in other research involving the NIS.
Study Population
Patients aged 18 years and older who underwent TVR (ICD-9-
CM procedure code 35.27 and 35.28) and TVr (ICD-9-CM
code 35.14) during the study period were identified. Patients
who underwent redo TV surgery (ICD-9-CM codes 35.20 and
35.21), those with congenital TV disease (ICD-9-CM codes
764.1, 746.2, 745.4, and 746.89), or those with infective
endocarditis (ICD-9-CM code 571.2) were excluded (Figure 1).
Trends of Use and Outcomes of TV Surgery
Temporal changes in clinical risk profile, hospital and
socioeconomic characteristics, type of surgery (TVR versus
TVr), and choice of prosthesis in patients undergoing TV
surgery were described. The patients were then divided into 2
groups: group 1 included patients who underwent TVR, and
group 2 included patients who underwent TVr. For each of the
2 groups, baseline patient comorbidities and procedural
characteristics were described. In-hospital mortality, postop-
erative morbidities, length of stay, disposition patterns, and
cost of care were also evaluated. Patient relevant descriptive
statistics are presented as frequencies with percentages for
categorical variables and as means with SDs for continuous
variables. Baseline characteristics were compared between
the groups using a Pearson v2 test for categorical variables
and an independent-sample t test for continuous variables. To
assess for monotonic trends of use and outcomes, we used
the nonparametric Mann-Kendal trend. To estimate the cost
of hospitalization, the NIS data were merged with cost/charge
ratios available from the Agency for Healthcare Research and
Quality Project. We estimated the cost of each inpatient stay
by multiplying the total hospital charge with cost/charge
ratios. Adjusted cost for each year was calculated in terms of
Figure 1. Study flow diagram. NE indicates national estimate;
and VSD, ventricular septal defect.
Clinical Perspective
What Is New?
• Tricuspid valve surgery for tricuspid regurgitation is infre-
quently performed in the United States.
• In-hospital morbidity and mortality and cost after isolated
tricuspid repair or replacement are high and did not change
significantly during the past decade.
• These suboptimal outcomes are likely related to patient risk
profile and referral timing rather than to the risk of the
operation.
What Are the Clinical Implications?
• These data may serve as a benchmark for the emerging
transcatheter tricuspid valve therapies.
• Further investigations are needed to assess the impact of
late referral on the outcomes of tricuspid valve surgery.
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the 2014 cost, after adjusting for inflation, according to the
latest consumer price index data released by the US
government, Department of Labor.22 All statistical analyses
were performed using SPSS, version 24 (IBM Corporation),
and R, version 3.3.1.
Results
A total of 9194 patients representing an NE of 45 477
patients who underwent TV surgery were included in our
study. Of those patients, 22.4% underwent TVR and 77.6%
underwent TVr. The number of patients undergoing TV surgery
for TR increased by 48% from 3100 in 2003 to 4600 in 2014
(Ptrend=0.009) (Figure 2, Table S1). Concomitant cardiac
surgery was performed in most patients: 61.4% and 85.2%
of patients who underwent TVR and TVr, respectively. During
the study period, there was a trend towards performing TV
surgery on patients with a higher prevalence of comorbidities
and during nonelective admissions (Table 1). Mitral valve
repair/replacement remained the most common concomitant
procedures with TV surgery.
Characteristics and Outcomes of Patients
Undergoing Isolated TVR
A total of 2062 patients (NE=10 207) underwent TVR during
the study period, of whom 795 (NE=3937) underwent isolated
TVR. Among patients who underwent TVR, the proportion who
underwent isolated TVR increased over time (Figure 3). Their
mean age was 5617 years, 57.6% were women, and 71.9%
were whites. Comorbidities were common, as illustrated in
Table 2. Interestingly, there was a significant number of
patients with chronic kidney (23%) and liver (11.1%) disease.
Most isolated TVRs were performed at teaching institutions
(86%) and during elective admissions (65%). Bioprosthetic
valves were used in 61.6% of patients.
In-hospital mortality was high (10.8%) and did not
improve over time (Figure 4). With the exception of stroke,
which occurred in 1.3% of patients, rates of major
postoperative morbidities were high: acute kidney injury
occurred in 27.8%, new dialysis was initiated in 5.5%, and
permanent pacemakers were implanted in 34.1% of
patients. Other postoperative complications were also not
uncommon, as summarized in Table 3. Resource use was
intensive; mean hospital length of stay was 1924 days,
and mean cost of hospitalization was $84 637$83 003.
Approximately one fifth of patients were discharged to an
intermediate-care facility.
Patients who underwent TVR concomitant with other
cardiac surgery during the same period represented a
different cohort of patients, as illustrated in Table S2.
Interestingly, despite being older and having higher incidences
of major morbidities, these patients experienced similar
unadjusted rates of death, stroke, and acute kidney injury
requiring dialysis compared with those who underwent
isolated TVR (Table S3).
Characteristics and Outcomes of Patients
Undergoing Isolated TVr
A total of 7132 patients (NE=35 270) underwent TVr, of
whom 569 (NE=2820) underwent isolated TVr. The number of
patients undergoing isolated TVr increased over time but
remained minuscule overall (Figure 5). Their mean age was
5418 years, 51.1% were women, and 64.6% were whites.
Despite the younger age of these patients, comorbidities were
common (Table 2). Interestingly, a significant percentage of
patients (45.8%) underwent isolated TVr during a nonelective
admission.
In-hospital mortality occurred in 8.1% of patients and
remained unchanged during the study period (Figure 4). Also,
rates of postoperative morbidities were high: stroke occurred
in 2.3%, a vascular complication requiring surgery occurred in
5.3%, dialysis-requiring kidney injury occurred in 4.4%, and
cardiac tamponade occurred in 2.5%. Also, 10.9% of patients
required a permanent pacemaker. The mean hospital length of
stay was 2326 days, and the mean cost of hospitalization
was $120 849$123 771. Intermediate-care facilities were
used in 20.1% of patients (Table 3).
Figure 2. National trends in the use of tricuspid valve surgery in
the United States between January 1, 2003 and December 31,
2014. NE indicates national estimate.
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Similar to what was observed in the TVR group, patients
who underwent TVr concomitant with other cardiac surgery
represented a distinct cohort of older patients with higher
prevalences of diabetes mellitus, chronic lung disease, atrial
fibrillation, and coronary and peripheral vascular disease
(Table S4). Despite that, these patients had lower unadjusted
in-hospital morbidity and mortality and cost than those who
underwent isolated TVr (Table S5).
Discussion
The main findings of the present investigation are as follows:
(1) Isolated TV surgery for TR is uncommon. Most TVR and TVr
procedures are done in conjunction with other cardiac
surgical procedures. (2) Patients who undergo isolated TV
surgery have a distinctive clinical risk profile compared with
those who undergo TV surgery concomitant with other cardiac
Table 1. Temporal Changes in Clinical Profiles in Patients Undergoing TVR Between January 1, 2003 and December 31, 2014
Characteristic
2003–2006
(N=625, NE=3059)
2007–2010
(N=644, NE=3219)
2011–2014
(N=793, NE=3928) P Value
Age, mean (SD and 25%, 50%,
and 75% quartiles), y
61 (15, 51, 62, 74) 60 (16, 49, 62, 73) 61 (16, 51, 65, 73) 0.332
Age >75 y, n (%) 126 (20.2) 116 (18) 155 (19.5) 0.603
Female sex, n (%) 61 (15) 60 (16) 61 (16) 0.327
Race, n (%) 0.295
White 310 (70) 363 (68.1) 498 (70.3)
Black 60 (13.5) 69 (12.9) 94 (13.3)
Hispanic 48 (10.8) 51 (9.6) 52 (7.3)
Medical comorbidity, n (%)
Hypertension 220 (36.1) 275 (42.7) 440 (55.5) <0.001
Diabetes mellitus 88 (14.1) 121 (18.8) 184 (23.2) <0.001
Prior sternotomy 48 (7.7) 68 (10.6) 106 (13.4) 0.003
Chronic pulmonary
disease
85 (13.6) 107 (16.6) 143 (18) 0.077
Atrial fibrillation/flutter 362 (57.9) 338 (52.5) 457 (57.6) 0.082
Anemia 96 (15.4) 132 (20.5) 207 (26.1) <0.001
Peripheral vascular
disease
22 (3.5) 41 (6.4) 75 (9.5) <0.001
Chronic renal disease 79 (12.6) 124 (19.3) 220 (27.7) <0.001
Hemodialysis 6 (1) 20 (3.1) 42 (5.3) <0.001
Coronary artery disease 140 (22.4) 174 (27) 194 (24.5) <0.001
Concomitant procedures, n (%)
Any concomitant cardiac
surgery
361 (57.7) 409 (63.5) 507 (63.9) <0.001
Coronary artery bypass 119 (19) 112 (17.4) 87 (11) <0.001
Aortic valve replacement 106 (17) 87 (13.5) 90 (11.3) 0.009
Mitral valve replacement 284 (45.4) 229 (35.6) 227 (28.6) <0.001
Mitral valve repair 30 (4.8) 26 (4) 24 (3) 0.222
Cox maze ablation 109 (17.4) 100 (15.5) 73 (9.2) <0.001
Left atrial appendage
ligation
0 (0) 40 (6.2) 90 (11.3) <0.001
Hospital characteristics, n (%)
Teaching hospital 475 (76) 496 (78.1) 687 (86.6) <0.001
Nonelective admission status, n (%) 361 (57.8) 409 (63.7) 507 (64) 0.031
NE indicates national estimate; and TVR, tricuspid valve replacement.
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surgery. (3) In-hospital mortality after isolated TVR and TVr is
high and did not change significantly during the past decade.
(4) Isolated TVR and TVr are associated with high rates of
postoperative morbidities, long hospitalizations, and substan-
tial cost. Isolated TVR is particularly associated with high
rates of permanent pacemaker implantation.
Moderate to severe TR affects up to 1.6 million patients in
the United States.23 Most patients experiencing significant TR
have concomitant valvular disease. Moderate-to-severe TR is
present in 30% to 50% of patients with severe mitral
regurgitation and in 12% to 25% of patients with severe
aortic stenosis.4,24–28 TR has been shown to be an indepen-
dent negative predictor of long-term survival among the
following: (1) patients with multivalvular disease undergoing
surgical or transcatheter aortic and mitral valve treat-
ment,1,2,4,25 (2) patients with heart failure who are treated
medically,24,29 and (3) patients with severe isolated TR who
are treated medically.30,31 There is also a growing body of
evidence suggesting a potential mortality benefit of early
treatment of TR in both patients with isolated TR and those
with TR concomitant with mitral valve disease.23,30,32 Despite
that, our study suggests that many patients with TR,
especially those with isolated TR, are not undergoing surgery
in contemporary practice: between 2003 and 2014, an
average of 3890 TV surgical procedures for TR were
performed annually in the United States; of these, only 570
(15%) were done for isolated TR. However, the low rates of TV
surgery for TR observed in this study need to be interpreted
with caution for several reasons: (1) The incidence rates of TR,
rates of referral, and refusal of surgery have not been well
studied and cannot be assessed with this data set; therefore,
the magnitude of undertreatment of TR cannot be ascer-
tained. (2) Despite the increasing acceptance of the potential
role of TV surgery in patients with TR, high-quality supportive
evidence is sparse. Indeed, most American College of
Cardiology/American Heart Association recommendations
on surgery for TR are assigned a weak (level C) class of
evidence and do not contain any class I indication for isolated
surgery for TR.33 Nevertheless, our data reveal that TV surgery
is infrequently performed, highlighting the need for further
investigations of the epidemiological features of TR and its
management patterns.12
Analysis of the baseline and procedural characteristics of
our study’s population revealed several intriguing findings: (1)
Patients who underwent isolated TV surgery were younger
than patients undergoing other valve surgery; the mean age
was 5617 and 5418 years for patients undergoing
isolated TVR and TVr, respectively. Emerging transcatheter
therapies for TV diseases may, therefore, need to demon-
strate not only safety and efficacy but also long-term
durability, perhaps longer than what has been expected in
the transcatheter therapies for the mitral and aortic valves. (2)
Patients who undergo isolated TVR or TVr represent a
distinctly different population than those who undergo TVR
or TVr combined with other cardiac surgery. The patients who
undergo isolated TVR or TVr have a higher prevalence of
chronic kidney and liver diseases and lower prevalences of
diabetes mellitus, atrial fibrillation, chronic lung disease, and
atherosclerotic coronary and peripheral vascular diseases.
The younger age and the higher prevalence of chronic kidney
and liver diseases in the isolated TV surgery groups may
suggest the presence of more severe TR-related symptoms in
this population, warranting isolated TV surgery. (3) A signif-
icant proportion (40%) of patients who underwent isolated
TV surgery for TR had their surgery during a nonelective
admission. This supports the perception that patients with TR
referred for TV surgery are frequently referred at later stages
of their disease. (4) Between 2003 and 2014, there was a
Figure 3. Temporal trend in isolated and combined tricuspid valve replacement for tricuspid regurgitation
between January 1, 2003 and December 31, 2014. NE indicates national estimate; and TVR, tricuspid valve
replacement.
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Table 2. Characteristics of Patients Undergoing Isolated TV Surgery Between January 1, 2003 and December 31, 2014
Characteristic
All Patients
(N=1364, NE=6757)
Isolated TVr Group
(N=569, NE=2820)
Isolated TVR Group
(N=795, NE=3937) P Value
Age, mean (SD and 25%, 50%,
and 75% quartiles), y
55 (17, 42, 57, 69) 54 (18, 39, 56, 68) 56 (17, 43, 57, 69) 0.022
Female sex, n (%) 749 (54.9) 291 (51.1) 458 (57.6) 0.018
Race, n (%) 0.018
White 773 (68.8) 307 (64.6) 466 (71.9)
Black 187 (16.7) 99 (20.8) 88 (13.6)
Hispanic 84 (7.5) 35 (7.4) 49 (7.6)
Medical comorbidity, n (%)
Hypertension 587 (43.4) 241 (42.4) 346 (44) 0.56
Diabetes mellitus 243 (17.8) 103 (18.1) 140 (17.6) 0.815
Prior sternotomy 198 (14.5) 64 (11.2) 134 (16.9) 0.004
Chronic pulmonary disease 187 (13.7) 81 (14.2) 106 (13.3) 0.633
Atrial fibrillation/flutter 609 (44.6) 243 (42.7) 366 (46) 0.222
Anemia 295 (21.6) 120 (21.1) 175 (22) 0.683
Coagulopathy 374 (27.6) 155 (27.3) 219 (27.9) 0.816
Conduction abnormalities 40 (2.9) 17 (3) 23 (2.9) 0.919
Peripheral vascular disease 91 (6.7) 37 (6.5) 54 (6.8) 0.832
Chronic renal disease 308 (22.6) 125 (22) 183 (23) 0.647
Hemodialysis 53 (3.9) 17 (3) 36 (4.5) 0.147
Coronary artery disease 182 (13.3) 84 (14.8) 98 (12.3) 0.192
Metastatic cancer 36 (2.7) 1 (0.2) 35 (4.5) <0.001
Liver disease 108 (8) 21 (3.7) 87 (11.1) <0.001
Liver cirrhosis 54 (4) 8 (1.4) 46 (5.8) <0.001
Hospital characteristics, n (%)
Teaching hospital 1171 (86.1) 489 (86.2) 682 (86) 0.899
Hospital bed size 0.033
Small 52 (3.8) 16 (2.8) 36 (4.5)
Medium 164 (12.1) 57 (10.1) 107 (13.5)
Large 1144 (84.1) 494 (87.1) 650 (82)
Rural location 15 (1.1) 6 (1.1) 9 (1.1) 0.894
Nonelective admission status, n (%) 538 (39.5) 260 (45.8) 278 (35) <0.001
Surgery on day 0–1 of admission 659 (54.8) 259 (53.4) 400 (55.7) 0.43
Primary payer, n (%) 0.019
Medicare/Medicaid 821 (60.2) 315 (55.4) 506 (63.6)
Private, including HMO 454 (33.3) 214 (37.6) 240 (30.2)
Self-pay/no charge/other 43 (3.2) 18 (3.2) 25 (3.1)
Median household income by percentile, n (%) 0.565
0–25th 359 (27.1) 159 (28.7) 200 (25.9)
26–50th 324 (24.4) 128 (23.1) 196 (25.4)
51–75th 321 (24.2) 137 (24.7) 184 (23.8)
76–100th 323 (24.3) 130 (23.5) 193 (25)
HMO indicates health maintenance organization; NE, national estimate; TV, tricuspid valve; TVr, TV repair; and TVR, TV replacement.
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clear and statistically significant trend towards performing TV
surgery in sicker patients with a higher prevalence of major
morbidities. (5) Contrary to what has been seen in treatment
of mitral regurgitation, current surgical treatment of isolated
TR remains primarily one of replacement, not repair.
Isolated TVR and TVr were associated with significant in-
hospital mortality (10.9% and 8.1%, respectively). Although
these mortality rates did not significantly improve over time,
this can partially be related to the trends towards treating
sicker patients in more recent years. There rates, however,
represent the outcomes of “all comers” who underwent TV
surgery and remain several folds higher than contemporary
operative mortality rates after isolated mitral valve repair
(1.4%–2.6%), mitral valve replacement (3.8%), and aortic valve
replacement (2.2%) in the United States.34–36 The frequency
of postoperative morbidities, the protracted hospital length of
stay, and the substantial cost of TV surgery were also
absorbing: (1) We noted high rates of postoperative perma-
nent pacemaker implantation (34.1% after isolated TVR and
10.9% after isolated TVr), much higher than what has been
reported after other valve surgical procedures.34–36 These
findings, nevertheless, are in line with prior single-center
reports showing pacemaker rates of 13% to 28% after TV
Figure 4. National trends in in-hospital mortality after isolated
tricuspid valve surgery for tricuspid regurgitation between January
1, 2003 and December 31, 2014. TVr indicates tricuspid valve
repair; and TVR, tricuspid valve replacement.
Table 3. Clinical Outcomes of Patients Undergoing Isolated TV Surgery Between January 1, 2003 and December 31, 2014
Characteristics
All Patients
(N=1364, NE=6757)
Isolated TVr Group
(N=569, NE=2820)
Isolated TVR Group
(N=795, NE=3937) P Value
Clinical outcome, n (%)
In-hospital death 132 (9.7) 46 (8.1) 86 (10.8) 0.093
Vascular complications 84 (6.2) 40 (7) 44 (5.5) 0.257
Vascular complications requiring surgery 57 (4.1) 30 (5.3) 27 (3.4) 0.088
Permanent pacemaker implantation 333 (24.4) 62 (10.9) 271 (34.1) <0.001
Clinical stroke 23 (1.7) 13 (2.3) 10 (1.3) 0.146
Acute kidney injury 413 (30.3) 192 (33.7) 221 (27.8) 0.018
Acute kidney injury requiring dialysis 69 (5.1) 25 (4.4) 44 (5.5) 0.343
Blood transfusion 485 (35.6) 186 (32.7) 299 (37.6) 0.061
Cardiac tamponade 23 (1.7) 14 (2.5) 9 (1.1) 0.06
Pneumonia 103 (7.5) 49 (8.6) 54 (6.8) 0.21
Prolonged ventilation 87 (6.4) 42 (7.4) 45 (5.7) 0.2
Wound infection 22 (1.6) 6 (1.1) 16 (2) 0.166
Pulmonary embolism 43 (3.2) 23 (4) 20 (2.5) 0.112
Deep venous thrombosis 15 (1.1) 9 (1.6) 6 (0.8) 0.149
Discharge status, n (%) 0.113
Discharged home 965 (70.7) 408 (71.8) 557 (70.2)
Discharged to SNF/NH/IC 261 (19.1) 114 (20.1) 147 (18.5)
Length of stay, mean (SD and 25%, 50%, and
75% quartiles), d
21 (25, 7, 12, 25) 23 (26, 7, 18, 28) 19 (24, 7, 12, 21) 0.013
Length of stay >5 d, n (%) 1173 (86) 483 (84.9) 690 (86.8) 0.317
Cost of hospitalization, mean (SD and 25%,
50%, and 75% quartiles), $
99 575 (99 421, 40 267,
65 906, 109 000)
119 055 (118 574, 38 901,
76 271, 170 760)
85 633 (80 272, 41 082,
62 255, 99 574)
<0.001
IC indicates intermediate-care facility; NE, national estimate; NH, nursing home; SNF, skilled nursing facility; TV, tricuspid valve; TVr, TV repair; and TVR, TV replacement.
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surgery and higher odds of needing a pacemaker after TVR
versus TVr.37,38 Several anatomical and technical factors have
been implicated in these high rates of pacemaker dependency
after TV surgery, including intraoperative hypothermia, car-
diopulmonary bypass duration, and the proximity of the
atrioventricular node and the atrioventricular nodal artery to
the tricuspid annulus.39,40 (2) New dialysis requirements were
high after isolated TVR and TVr (5.5% and 4.4%, respectively).
In contemporary practice, <2% of patients undergoing isolated
aortic valve replacement and 1% to 2% of patients undergoing
mitral valve surgery require dialysis postoperatively.34–36 This
is likely because of the high prevalence of chronic renal and
liver disease in patients with TR attributable to right-sided
heart failure. (3) Postoperative stroke rate was relatively high
(2.3%) among patients who underwent isolated TVr. Further
studies are needed to identify the root cause of this higher
than expected rate. (4) Mean lengths of stay in our study
were 1924 and 2326 days after TVR and TVr, respec-
tively. These hospitalizations are significantly longer than
contemporaneous hospital length of stay after aortic and
mitral valve replacement (6 and 7 days, respectively).34–36
The protracted stays were also associated with a substantial
cost: $84 637$83 003 for isolated TVR and
$120 849$123 771 for isolated TVr. The higher cost
associated with TVr can be partially explained by the
differences in patient risk profiles and demographics and
the longer hospitalizations in the TVr group.
These cost values, nevertheless, are 2-fold higher than
parallel cost data published from the NIS for isolated aortic and
mitral valve surgical procedures.41 These data may be encour-
aging to the rising transcatheter TV therapies. These repair and
replacement systems, if deemed safe and effective, are likely to
perform well in cost-effectiveness analyses because of the
substantial cost resource use associated with TV surgery.
The discussion of these findings would not be complete
without alluding to the impact of late presentation on the
outcomes of TV surgery. Kilic et al demonstrated an inverse
relationship between the duration of disease and outcomes.8 In
their study, surrogates for late presentation exerted a greater
effect onmortality than the addition of concomitant other valves
procedures. Although identification of disease duration in our
database isnotpossible, thehighprevalenceofchronic renaland
liver disease and the high proportion of nonelective TV
operations indicate that late presentation may be common
among patients with TR undergoing TVR or TVr in current
practice.
Limitations
This study has several limitations. (1) The NIS is derived from
hospital claims data and subject to the shortcomings of other
administrative data sets. Inconsistencies related to diagnosis
coding may underestimate or overestimate adverse events.
However, the Agency for Healthcare Research and Quality
quality control measures should minimize these possibilities.
(2) Cause of TV disease, left ventricular ejection fraction, right
ventricular function, duration of TV disease, and baseline and
postoperative echocardiographic data are not captured in the
NIS. Also, details on specific outcomes beyond hospital
discharge are not available in the NIS. (3) Finally, this study
included patients who were likely deemed acceptable surgical
candidates, which may underestimate the actual morbidity
and mortality for higher-risk patients who are being denied TV
surgery. Nevertheless, this study provides the largest “real-
world” outcomes data on TV surgery for TR, offering important
insights into a cohort of patients who will be the focus of
multiple investigations in the field of transcatheter TVR and
TVr.
Figure 5. Temporal trend in isolated and combined tricuspid valve repair for tricuspid regurgitation between
January 1, 2003 and December 31, 2014. NE indicates national estimate; and TVr, tricuspid valve repair.
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Conclusions
In contemporary practice, patients who undergo isolated TVR
and TVr experience high postoperative morbidity and mortal-
ity, lengthy hospitalizations, and substantial cost. Further
investigations to assess the impact of late referral on these
outcomes are needed.
Disclosures
None.
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Table S1. Estimated Numbers of Tricuspid Valve Surgeries Performed in the 
United States Between 2003 and 2014 
 
 Number of Tricuspid Valve Surgeries in The United States 
Year 
Total Number 
 (NE)  
Tricuspid 
Regurgitation 
Congenital 
Heart Defect 
Infective  
Endocarditis 
2003 800 (3849) 642 (3100) 74 (349) 92 (441) 
2004 609 (2958) 431 (2096) 106 (511) 75 (366) 
2005 1010 (5030) 680 (3394) 238 (1188) 96 (468) 
2006 1020 (5029) 775 (3766) 157 (829) 100 (492) 
2007 844 (4283) 656 (3361) 122 (581) 76 (388) 
2008 1002 (4964) 793 (3934) 108 (531) 104 (513) 
2009 1179 (5786) 938 (4595) 128 (638) 122 (598) 
2010 977 (4981) 701 (3569) 172 (879) 116 (595) 
2011 1263 (5991) 913 (4334) 220 (1032) 140 (670) 
2012 1251 (6255) 847 (4235) 258 (1290) 159 (795) 
2013 1289 (6445) 918 (4590) 218 (1090) 157 (785) 
2014 1332 (6660) 920 (4600) 257 (1285) 164 (820) 
 
NE; national estimate 
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Table S2. Characteristics of Patients Undergoing Tricuspid Valve 
Replacement Between 2003-2014  
 
Characteristic 
All Patients 
(N=2062 
NE=10207) 
Combined TVR 
(N=1267 
NE=6270) 
Isolated TVR 
(N=795 
NE=3937) P value 
Age- mean (SD), y 61 (16) 64 (15) 56 (17) <0.001 
Female - no. (%) 1249 (60.6) 791 (62.4) 458 (57.6) 0.029 
Race- no. (%)  0.146 
   White 1171 (69.5) 705 (68.1) 466 (71.9) 
    Black 223 (13.2) 135 (13) 88 (13.6) 
   Hispanic 151 (9) 102 (9.8) 49 (7.6) 
Medical Comorbidity- no (%)  
   Hypertension 935 (45.7) 589 (46.7) 346 (44) 0.235 
   Diabetes 393 (19.1) 253 (20) 140 (17.6) 0.184 
   Prior Sternotomy 222 (10.8) 88 (6.9) 134 (16.9) <0.001 
   Chronic Pulmonary Disease 335 (16.2) 229 (18.1) 106 (13.3) 0.005 
   Atrial Fibrillation/Flutter 1157 (56.1) 791 (62.4) 366 (46) <0.001 
   Anemia 435 (21.1) 260 (20.5) 175 (22) 0.419 
   Coagulopathy 604 (29.5) 385 (30.5) 219 (27.9) 0.198 
   Conduction Abnormalities 59 (2.9) 36 (2.8) 23 (2.9) 0.945 
   Peripheral Vascular Disease 138 (6.7) 84 (6.6) 54 (6.8) 0.886 
   Chronic Renal Disease  423 (20.5) 240 (18.9) 183 (23) 0.026 
   Hemodialysis 68 (3.3) 32 (2.5) 36 (4.5) 0.013 
   Coronary Artery Disease 508 (24.6) 410 (32.4) 98 (12.3) <0.001 
   Metastatic Cancer 67 (3.3) 32 (2.5) 35 (4.5) 0.018 
   Liver Disease 160 (7.8) 73 (5.8) 87 (11.1) <0.001 
   Liver Cirrhosis 86 (4.2) 40 (3.2) 46 (5.8) 0.004 
Type of Valve Replacement- no (%)     
   Mechanical  988 (47.9) 683 (53.9) 305 (38.4) <0.001 
   Bioprosthetic   1074 (52.1) 584 (46.1) 490 (61.6) <0.001 
Concomitant Procedures- no (%)  
   Percutaneous coronary intervention  13 (0.6) 13 (1) 0 (0) <0.001 
   Coronary artery bypass 318 (15.4) 318 (25.1) 0 (0) <0.001 
   Aortic valve replacement  283 (13.7) 283 (22.3) 0 (0) <0.001 
   Mitral valve replacement 740 (35.9) 740 (58.4) 0 (0) <0.001 
   Mitral valve repair  80 (3.9) 80 (6.3) 0 (0) <0.001 
   Cox Maze Ablation 282 (13.7) 282 (22.3) 0 (0) <0.001 
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 * IABP; intraortic balloon pump, LV; left ventricular   
   Left atrial appendage ligation 130 (6.3) 130 (10.3) 0 (0) <0.001 
   Open ASD\VSD Repair 199 (9.7) 199 (15.7) 0 (0) <0.001 
   IABP*/LV** Assist Device Use 168 (8.1) 139 (11) 29 (3.6) <0.001 
Hospital characteristics- no (%)  
   Teaching Hospital 1658 (80.8) 976 (77.5) 682 (86) <0.001 
   Hospital bed size  0.638 
         Small 93 (4.5) 57 (4.5) 36 (4.5) 
 
         Medium  296 (14.4) 189 (15) 107 (13.5) 
         Large 1664 (81.1) 1014 (80.5) 650 (82) 
   Rural location  23 (1.1) 14 (1.1) 9 (1.1) 0.96 
Non-elective Admission Status- no (%) 782 (38) 504 (39.8) 278 (35) 0.028 
Surgery on day 0-1 of admission 990 (56) 590 (56.1) 400 (55.7) 0.859 
Primary Payer- no (%)  0.373 
   Medicare / Medicaid 1359 (65.9) 853 (67.3) 506 (63.6) 
 
   Private including HMO 583 (28.3) 343 (27.1) 240 (30.2) 
   Self-pay/No charge/Other 64 (3.1) 39 (3.1) 25 (3.1) 
Median Household Income- no (%)    0.666 
   1. 0-25th percentile 526 (26.1) 326 (26.3) 200 (25.9) 
 
   2. 26-50th percentile 494 (24.5) 298 (24) 196 (25.4) 
   3. 51-75th percentile 506 (25.1) 322 (26) 184 (23.8) 
   4. 76-100th percentile 487 (24.2) 294 (23.7) 193 (25) Dow
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Table S3. Clinical Outcomes of Patients Undergoing Tricuspid Valve 
Replacement Between 2003-2014  
 
 
 
 
* SNF; Skilled nursing facility, NH; Nursing Home; IC; Intermediate Care Facility  
  
 
All Patients 
(N=2062 
NE=10207) 
Combined TVR 
(N=1267 
NE=6270) 
Isolated TVR 
(N=795 
NE=3937) P value 
Clinical Outcome- no (%)  
   In-Hospital Death 245 (11.9) 159 (12.6) 86 (10.8) 0.236 
   Vascular Complications 109 (5.3) 65 (5.1) 44 (5.5) 0.69 
   Vascular Complications Requiring Surgery 61 (3) 34 (2.7) 27 (3.4) 0.353 
   Permanent Pacemaker Implantation 627 (30.4) 356 (28.1) 271 (34.1) 0.004 
   Clinical Stroke 40 (1.9) 30 (2.4) 10 (1.3) 0.075 
   Acute Kidney Injury  611 (29.6) 390 (30.8) 221 (27.8) 0.149 
   Acute Kidney Injury Requiring Dialysis  114 (5.5) 70 (5.5) 44 (5.5) 0.992 
   Blood Transfusion 750 (36.4) 451 (35.6) 299 (37.6) 0.355 
   Cardiac Tamponade 24 (1.2) 15 (1.2) 9 (1.1) 0.915 
   Pneumonia 145 (7) 91 (7.2) 54 (6.8) 0.736 
   Prolonged ventilation  162 (7.9) 117 (9.2) 45 (5.7) 0.003 
   Wound infection 38 (1.8) 22 (1.7) 16 (2) 0.65 
   Pulmonary embolism 35 (1.7) 15 (1.2) 20 (2.5) 0.023 
   Deep venous thrombosis 21 (1) 15 (1.2) 6 (0.8) 0.345 
Discharge Status- no (%)  <0.001 
   Discharged Home 1275 (61.9) 718 (56.8) 557 (70.2) 
    Discharged SNF/NH/IC* 534 (25.9) 387 (30.6) 147 (18.5) 
Length of Stay- mean (SD), d 19 (20) 19 (17) 19 (24) 0.413 
Length of stay > 5 days  1850 (89.7) 1160 (91.6) 690 (86.8) 0.001 
Cost of hospitalization- mean (SD), $  89760 (79637) 92958 (77326) 84637 (83003) 0.028 
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Table S4. Characteristics of Patients Undergoing Tricuspid Valve Repair 
Between 2003-2014  
 
Characteristic 
All Patients 
(N=7132 
NE=35270) 
Combined TVr 
(N=6563 
NE=32450) 
Isolated TVr 
(N=569 
NE=2820) P value 
Age- mean (SD), y 66 (14) 67 (13) 54 (18) <0.001 
Female - no. (%) 4298 (60.3) 4007 (61.1) 291 (51.1) <0.001 
Race- no. (%)  <0.001 
   White 4011 (71.3) 3704 (71.9) 307 (64.6) 
    Black 720 (12.8) 621 (12.1) 99 (20.8) 
   Hispanic 404 (7.2) 369 (7.2) 35 (7.4) 
Medical Comorbidity- no (%)  
   Hypertension 3740 (52.7) 3499 (53.6) 241 (42.4) <0.001 
   Diabetes 1520 (21.3) 1417 (21.6) 103 (18.1) 0.051 
   Prior Sternotomy 403 (5.7) 339 (5.2) 64 (11.2) <0.001 
   Chronic Pulmonary Disease 1389 (19.5) 1308 (19.9) 81 (14.2) 0.001 
   Atrial Fibrillation/Flutter 4792 (67.2) 4549 (69.3) 243 (42.7) <0.001 
   Anemia 1441 (20.2) 1321 (20.1) 120 (21.1) 0.584 
   Coagulopathy 1995 (28.1) 1840 (28.2) 155 (27.3) 0.647 
   Conduction Abnormalities 191 (2.7) 174 (2.7) 17 (3) 0.633 
   Peripheral Vascular Disease 571 (8) 534 (8.1) 37 (6.5) 0.168 
   Chronic Renal Disease  1286 (18) 1161 (17.7) 125 (22) 0.011 
   Hemodialysis 163 (2.3) 146 (2.2) 17 (3) 0.243 
   Coronary Artery Disease 2499 (35) 2415 (36.8) 84 (14.8) <0.001 
   Metastatic Cancer 12 (0.2) 11 (0.2) 1 (0.2) 0.967 
   Liver Disease 198 (2.8) 177 (2.7) 21 (3.7) 0.171 
   Liver Cirrhosis 80 (1.1) 72 (1.1) 8 (1.4) 0.502 
Concomitant Procedures- no (%)  
   Percutaneous coronary intervention  42 (0.6) 42 (0.6) 0 (0) 0.056 
   Coronary artery bypass 1886 (26.4) 1886 (28.7) 0 (0) <0.001 
   Aortic valve replacement  1507 (21.1) 1507 (23) 0 (0) <0.001 
   Mitral valve replacement 2653 (37.2) 2653 (40.4) 0 (0) <0.001 
   Mitral valve repair  2615 (36.7) 2615 (39.8) 0 (0) <0.001 
   Cox Maze Ablation 1827 (25.6) 1827 (27.8) 0 (0) <0.001 
   Left atrial appendage ligation 950 (13.3) 950 (14.5) 0 (0) <0.001 
   Open ASD\VSD Repair 799 (11.2) 799 (12.2) 0 (0) <0.001 
   IABP*/LV** Assist Device Use 697 (9.8) 615 (9.4) 82 (14.4) <0.001 
Hospital characteristics- no (%)  
   Teaching Hospital 5285 (74.4) 4796 (73.3) 489 (86.2) <0.001 
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* IABP; intraortic balloon pump, LV; left ventricular   
   Hospital bed size  <0.001 
         Small 374 (5.3) 358 (5.5) 16 (2.8) 
 
         Medium  1086 (15.3) 1029 (15.7) 57 (10.1) 
         Large 5647 (79.5) 5153 (78.8) 494 (87.1) 
   Rural location  162 (2.3) 156 (2.4) 6 (1.1) 0.042 
Non-elective Admission Status- no (%) 2488 (34.9) 2228 (34) 260 (45.8) <0.001 
Surgery on day 0-1 of admission 3540 (62.6) 3281 (63.5) 259 (53.4) <0.001 
Primary Payer- no (%)  <0.001 
   Medicare / Medicaid 5031 (70.5) 4716 (71.9) 315 (55.4) 
 
   Private including HMO 1783 (25) 1569 (23.9) 214 (37.6) 
   Self-pay/No charge/Other 153 (2.1) 135 (2.1) 18 (3.2) 
Median Household Income- no (%)    <0.001 
   1. 0-25th percentile 1704 (24.5) 1545 (24.1) 159 (28.7) 
 
   2. 26-50th percentile 1838 (26.4) 1710 (26.7) 128 (23.1) 
   3. 51-75th percentile 1806 (25.9) 1669 (26) 137 (24.7) 
   4. 76-100th percentile 1614 (23.2) 1484 (23.2) 130 (23.5) 
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Table S5. Clinical Outcomes of Patients Undergoing Tricuspid Valve Repair 
Between 2003-2014  
 
 
* SNF; Skilled nursing facility, NH; Nursing Home; IC; Intermediate Care Facility  
 
 
All Patients 
(N=7132 
NE=35270) 
Combined TVr 
(N=6563 
NE=32450) 
Isolated TVr 
(N=569 
NE=2820) P value 
Clinical Outcome- no (%)  
   In-Hospital Death 521 (7.3) 475 (7.2) 46 (8.1) <0.001 
   Vascular Complications 337 (4.7) 297 (4.5) 40 (7) 0.375 
   Vascular Complications Requiring Surgery 213 (3) 183 (2.8) 30 (5.3) 0.023 
   Permanent Pacemaker Implantation 1083 (15.2) 1021 (15.6) 62 (10.9) <0.001 
   Clinical Stroke 139 (1.9) 126 (1.9) 13 (2.3) 0.482 
   Acute Kidney Injury  1746 (24.5) 1554 (23.7) 192 (33.7) <0.001 
   Acute Kidney Injury Requiring Dialysis  228 (3.2) 203 (3.1) 25 (4.4) 0.871 
   Blood Transfusion 2546 (35.7) 2360 (36) 186 (32.7) 0.015 
   Cardiac Tamponade 71 (1) 57 (0.9) 14 (2.5) 0.03 
   Pneumonia 411 (5.8) 362 (5.5) 49 (8.6) 0.001 
   Prolonged ventilation  374 (5.2) 332 (5.1) 42 (7.4) 0.011 
   Wound infection 106 (1.5) 100 (1.5) 6 (1.1) 0.002 
   Pulmonary embolism 60 (0.8) 37 (0.6) 23 (4) 0.33 
   Deep venous thrombosis 62 (0.9) 53 (0.8) 9 (1.6) 0.126 
Discharge Status- no (%)  <0.001 
   Discharged Home 4531 (63.6) 4123 (62.9) 408 (71.8) 
    Discharged SNF/NH/IC* 2068 (29) 1954 (29.8) 114 (20.1) 
Length of Stay- mean (SD), d 16 (15) 15 (14) 23 (26) <0.001 
Length of stay > 5 days  6290 (88.2) 5807 (88.5) 483 (84.9) 0.011 
Cost of hospitalization- mean (SD), $  78315.54 (67255) 74761 (58820) 120849 (123771) <0.001 
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